๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Brain Metastases
Clinical trial register · China

Brain Metastases Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 4 Shanghai 4 Beijing 4 Changsha 2 Zhengzhou 1
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou4 Shanghai4 Beijing4 Changsha2 Zhengzhou1
All 13 locations
Target enrolment
to

Brain Metastases trials in China

20 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases
NCT07539753Breast Cancer, Brain Metastases, HR+/HER2- Breast Cancer
Nanfang Hospital, Southern Medical University
Phase 2
46
Guangzhou
2026-06-01
Recruiting
Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases
NCT07481786Lung Adenocarcinoma, Brain Metastases, Radiotherapy, Intensity-Modulated, Bevacizumab
Sun Yat-sen University
Phase 3
220
Chongqing, Guangzhou
2026-03-20
Not yet open
Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
NCT07365410Non-small Cell Lung Cancer (NSCLC), Brain Metastases, Furmonertinib, EGFR Mutation
Tianjin Medical University Cancer Institute and Hospital
Phase 2
60
Tianjin
2026-01
Recruiting
Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases
NCT07100600HER2-positive Advanced Breast Cancer, Brain Metastases, Radiotherapy
Henan Cancer Hospital
Phase 2
224
Zhengzhou
2025-08-30
Recruiting
BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
NCT06793332Triple-Negative Breast Cancer (TNBC), Brain Metastases
Fudan University
Phase 2
39
Shanghai
2024-12-17
Recruiting
Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases
NCT06702826Non Small Cell Lung Cancer, Brain Metastases, Stereotactic Radiation, Immunotherapy
Rongrong Zhou
Phase 2
20
Changsha
2024-11-01
Recruiting
TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas
NCT06640582Brain Tumor, Brain Metastases, Brain Cancer, Glioma
Essen Biotech
Phase 1/2
85
Beijing
2024-10-20
Recruiting
Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study
NCT06728865Non-small Cell Lung Cancer (NSCLC), EGFR Mutation-Positive Lung Cancer, Brain Metastases, Leptomeningeal Metastases
Li-kun Chen
Phase 2
70
Guangzhou
2024-09-04
Active, closed
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
NCT06282874Carcinoma, Non-Small-Cell Lung, Brain Metastases, Leptomeningeal Metastasis
Guangdong Association of Clinical Trials
Phase 4
41
Dongguan, Foshan, Guangzhou
2024-08-01
Recruiting
Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis
NCT06501391NSCLC Stage IV, Brain Metastases
Fudan University
Phase 2
54
Shanghai
2024-07-01
Recruiting
SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer
NCT06476093Non-Small-Cell Lung Cancer, Brain Metastases
The First People's Hospital of Lianyungang
Not applicable
46
Lianyungang
2024-07-01
Recruiting
WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases
NCT06243003SCLC,Extensive Stage, Brain Metastases
Fudan University
Phase 1/2
56
Shanghai
2024-01-15
Recruiting
SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC
NCT06457906Small-cell Lung Cancer, Brain Metastases, SRS, Stereotactic Radiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
340
Beijing
2023-09-01
Recruiting
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
NCT05948813NSCLC, EGFR Activating Mutation, Brain Metastases
TYK Medicines, Inc
Phase 2
420
Beijing
2023-08-17
Active, closed
SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI
NCT06020066Brain Metastases, Non-small Cell Lung Cancer
Fudan University
Phase 2
202
Shanghai
2023-08-10
Recruiting
Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases
NCT05768490Brain Metastases, Radiotherapy, EGFR Activating Mutation
Sun Yat-sen University
Phase 3
232
Guangdong
2023-03-15
Recruiting
UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases
NCT05535413Metastatic HER2 Negative Breast Carcinoma, Brain Metastases, Capecitabine, UDT1
Hunan Cancer Hospital
Phase 1/2
30
Changsha
2023-01-01
Active, closed
Hippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost for BMs of NSCLC
NCT06557187Brain Metastases, Non-small Cell Lung Cancer
Yatian Liu
Not applicable
40
Nanjing
2021-01-01
Active, closed
X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases
NCT03753685Nonsmall Cell Lung Cancer, Brain Metastases
Fudan University
Phase 2
27
Shenzhen
2019-04-12
Rows per page Showing 1–20 of 20
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/brain-metastases

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 20 of those studies listing the condition Brain Metastases.

How many Brain Metastases trials are recruiting in China?

13 of the 20 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 4 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Brain Metastases), 20 studies
PhaseStudiesRecruitingShare
Phase 210650%
Phase 1/23315%
Phase 33315%
Not applicable2110%
Observational105%
Phase 4105%

Most active sponsors

Lead sponsors with the most studies (Brain Metastases)
Lead sponsorStudiesRecruiting
Fudan University53
Sun Yat-sen University22
Cancer Institute and Hospital, Chinese Academy of Medical Sciences11
Essen Biotech11
Guangdong Association of Clinical Trials10
Henan Cancer Hospital11
Hunan Cancer Hospital11
Li-kun Chen11
Ming Yang10
Nanfang Hospital, Southern Medical University10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.